UBS Group AG Purchases 243,855 Shares of Arcus Biosciences, Inc. $RCUS

UBS Group AG lifted its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 145.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 411,259 shares of the company’s stock after purchasing an additional 243,855 shares during the period. UBS Group AG owned about 0.38% of Arcus Biosciences worth $9,800,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in RCUS. AQR Capital Management LLC boosted its holdings in Arcus Biosciences by 253.9% in the first quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock valued at $714,000 after acquiring an additional 65,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Arcus Biosciences by 10.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock valued at $297,000 after buying an additional 3,565 shares during the period. Millennium Management LLC lifted its position in Arcus Biosciences by 29.2% during the first quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock valued at $9,378,000 after buying an additional 270,253 shares during the period. Goldman Sachs Group Inc. lifted its position in Arcus Biosciences by 106.2% during the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock valued at $7,177,000 after buying an additional 470,755 shares during the period. Finally, Strs Ohio purchased a new position in Arcus Biosciences during the first quarter valued at $67,000. Institutional investors own 92.89% of the company’s stock.

Insider Activity at Arcus Biosciences

In other news, CFO Robert C. Goeltz II sold 7,763 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $25.63, for a total transaction of $198,965.69. Following the completion of the sale, the chief financial officer owned 84,161 shares of the company’s stock, valued at $2,157,046.43. This represents a 8.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on RCUS shares. Morgan Stanley raised their price objective on Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Monday, April 20th. Wedbush lifted their target price on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Finally, The Goldman Sachs Group lifted their target price on shares of Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $33.33.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS opened at $23.82 on Friday. Arcus Biosciences, Inc. has a fifty-two week low of $7.91 and a fifty-two week high of $28.72. The business has a 50-day simple moving average of $23.33 and a two-hundred day simple moving average of $22.38. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.04 and a current ratio of 4.04. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of -7.49 and a beta of 0.87.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business had revenue of $17.00 million during the quarter, compared to analysts’ expectations of $29.49 million. During the same period last year, the firm posted ($1.14) EPS. Arcus Biosciences’s quarterly revenue was down 39.3% compared to the same quarter last year. On average, analysts expect that Arcus Biosciences, Inc. will post -3.53 earnings per share for the current year.

Arcus Biosciences Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.